Payment overview · 2025
General Payments
$1,768.10
96 reported records · 21 companies
Healthcare provider profile · identity verified
David A Chalk, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANNISTON, AL · NPI 1134106800
Verified facts
What the public records show
CMS Open Payments records show David A Chalk, MD received $1,768.10 in general payments during 2025 across 96 reported records.
Novo Nordisk Inc accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $299.65 | 16.9% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $190.17 | 10.8% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $186.54 | 10.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $182.00 | 10.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.70 | 8.3% | 11 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $115.36 | 6.5% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $102.69 | 5.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.64 | 4.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.39 | 4.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.39 | 4.0% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.60 | 3.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.63 | 2.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.34 | 1.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.99 | 1.6% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.01 | 1.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $21.53 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.02 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.94 | 1.2% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $18.76 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.20 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.55 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,768.10 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $186.54 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $182.00 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $170.21 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $152.36 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $147.29 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.60 | 10 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $115.36 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $102.69 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $83.64 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.39 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.39 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.39 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $67.60 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.19 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.63 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $28.10 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.01 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 158 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 148 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
158 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 170 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 460 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 117 |
| Gabapentin | Gabapentin | 342 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 303 | 80 |
| Losartan Potassium | Losartan Potassium | 270 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 260 | 73 |
| Clonazepam | Clonazepam | 239 | 37 |
| Alprazolam | Alprazolam | 231 | 37 |
| Tramadol Hcl | Tramadol Hcl | 226 | 62 |
| Carvedilol | Carvedilol | 220 | 63 |
| Omeprazole | Omeprazole | 216 | 67 |
| Trazodone Hcl | Trazodone Hcl | 200 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 194 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 171 | 47 |
| Simvastatin | Simvastatin | 169 | 53 |
| Metformin Hcl Er | Metformin Hcl | 159 | 50 |
| Eliquis | Apixaban | 158 | 38 |
| Ozempic | Semaglutide | 148 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 39 |
| Furosemide | Furosemide | 141 | 56 |
| Lisinopril | Lisinopril | 134 | 41 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Potassium Chloride | Potassium Chloride | 124 | 46 |
| Sertraline Hcl | Sertraline Hcl | 123 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 27 |
| Meloxicam | Meloxicam | 120 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 118 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 113 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 28 |
| Glimepiride | Glimepiride | 102 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 32 |
| Montelukast Sodium | Montelukast Sodium | 97 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 31 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 26 |
| Azithromycin | Azithromycin | 86 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 27 |
| Mounjaro | Tirzepatide | 83 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 23 |
| Fluconazole | Fluconazole | 68 | 34 |
| Ezetimibe | Ezetimibe | 67 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 28 |
| Prednisone | Prednisone | 65 | 35 |
| Benazepril Hcl | Benazepril Hcl | 64 | 18 |
| Buspirone Hcl | Buspirone Hcl | 63 | 15 |
| Famotidine | Famotidine | 63 | 25 |
| Allopurinol | Allopurinol | 61 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 23 |
| Pregabalin | Pregabalin | 58 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Atenolol | Atenolol | 50 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 50 | 14 |
| Methylprednisolone | Methylprednisolone | 49 | 43 |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Meclizine Hcl | Meclizine Hcl | 48 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 34 |
| Temazepam | Temazepam | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Estradiol | Estradiol | 44 | 13 |
| Donepezil Hcl | Donepezil Hcl | 43 | 13 |
| Ondansetron Odt | Ondansetron | 43 | 15 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 11 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 31 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Jardiance | Empagliflozin | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 13 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 12 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Cefdinir | Cefdinir | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,768.10 · 96 records | Novo Nordisk Inc | AIRSUPRA, AVYCAZ, BREZTRI, CAPLYTA, COLLAGENASE SANTYL, Cologuard Collection Kit, DALVANCE, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE, GVOKE HYPOPEN, JARDIANCE, JOURNAVX, Kerendia, Kimyrsa, Korlym, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Orbactiv, Ozempic, REPATHA, REXULTI, Rezzayo, Rybelsus, TEFLARO, TRELEGY ELLIPTA, VRAYLAR, Wegovy, ZERBAXA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error